
The company is aggressively expanding, targeting over 300 locations system‑wide by 2026, with early test markets delivering higher average ticket sizes, increased transaction volume, and a near‑4% lift in comparable sales. Technically, the stock has pulled back from a recent rally and is now consolidating in a constructive price zone, with momentum indicators cooling. This creates a window to sell options well below the current price, collecting premium while positioning for potential share ownership. The analyst recommends employing the wheel strategy to capture upside with limited downside risk.

In this episode Edward Corona examines Wingstop’s latest earnings report, noting an 8.6% revenue increase to $175 million but a miss on expectations and a 5.8% decline in domestic comparable sales—the weakest stretch of FY25. Despite the “meh” headline numbers, the...

In this episode the host reviews a recent earnings event and observes that the stock is stabilizing, hinting at potential upward momentum. To capitalize on this, they outline a covered‑call strategy that generates upfront premium, reduces the effective cost basis,...

In this episode, Edward Corona examines Dutch Bros (BROS), a drive‑thru coffee chain that just reported one of its strongest quarters, asking whether the stock is showing an early momentum shift that could signal a broader market turn. He breaks...

In this episode Edward Corona examines Instacart’s (CART) recent earnings report, highlighting that while the company missed GAAP EPS expectations, its stock surged over 9%. He explains that the market focused on underlying growth metrics—especially rising customer spend—and ignored the...

The episode dissects Robinhood's latest earnings, highlighting a modest EPS beat but a revenue miss at $1.28 billion, with investors zeroing in on the platform's faltering crypto segment. It examines how the slowdown in crypto trading revenue is weighing on the...

In this episode Edward Corona dissects the sudden 16% plunge of Hims & Hers Health (HIMS), linking it to a dual blow from GLP‑1 hype‑driven expectations and mounting legal and FDA scrutiny. He explains how lawsuits and regulatory pressure are...

In this episode, Edward Corona dissects Molina Healthcare’s disastrous earnings report, highlighting a stark mismatch between projected rates and actual costs that caused the stock to plunge over 25% in a single day. He breaks down the underlying financial math,...